TAM
LXRX icon

Tucker Asset Management’s Lexicon Pharmaceuticals LXRX Stock Holding History

Tucker Asset Management’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-27,596
Closed -$63.2K – 1487
2023
Q2 		$63.2K Buy
+27,596
New +$73.3K 0.02% 226

Other funds holding LXRX

AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

Tucker Asset Management's LXRX Position: Q3 2023 in Review

Tucker Asset Management sold out of Lexicon Pharmaceuticals (LXRX) in Q3 2023, closing a stake of 27,596 shares — an estimated $63.2K sold.

Tucker Asset Management first reported a position in LXRX in Q2 2023 and held it in 1 quarter. The position peaked at $63.2K in Q2 2023. 112 funds tracked by Wall St. Rank hold LXRX as of Q3 2023.

  • Tucker Asset Management reported no remaining Lexicon Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
  • Tucker Asset Management sold 27,596 Lexicon Pharmaceuticals shares in Q3 2023, an estimated $63.2K.
  • Tucker Asset Management first reported a position in Lexicon Pharmaceuticals in Q2 2023 and held it in 1 quarter.
  • Tucker Asset Management's Lexicon Pharmaceuticals position peaked at $63.2K in Q2 2023.
  • 112 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q3 2023.

Based on Tucker Asset Management's 13F filing for Q3 2023, filed 4 Dec 2023.